idea-011 · human · US
For continuous ambulatory ECG (electrocardiogram)-based screening, as an adjunct to and not a; replacement for laboratory potassium measurement, to flag possible hyperkalemia between; scheduled visits in adult outpatients with chronic kidney disease or heart failure; undergoing initiation or up-titration of a renin-angiotensin-aldosterone system inhibitor,; with any flagged reading requiring confirmatory testing before a clinical decision is made.
Back in research. The gate sent it there with 8 of 9 factors verified; nothing for you to decide yet. No department has been asked. 5 of 39 claims verified. Nobody has yet written down what it rests on.
Adhesive-patch single- or multi-lead ECG sensor worn continuously between clinic visits, streaming waveform data to a paired reader; an onboard or cloud deep-learning model scores ECG morphology (e.g. T-wave changes historically associated with hyperkalemia) for hyperkalemia risk and pushes an alert to the prescribing clinic, prompting a confirmatory lab or point-of-care potassium draw rather than replacing one
In the mechanism, as the candidate file states it — the plain-language paragraph in ## Wrap has not been written yet. Domain: potassium-monitoring-ckd
No business case yet, so nothing here says who writes the cheque. /business-case idea-011 builds one.
What this idea rests on that is not yet known, in the order this idea's own decision queue puts it: worst if false first, cheapest to settle first inside that. The first row is open; open any other for what would settle it.
This idea is unassessed, so nobody has yet named the few things it rests on. Until then, the gaps below are the rubric factors that are unscored or carry an open question. /assess idea-011 replaces this list with the real one.
Why it scored what it did: Claims 1-2: AliveCor received Breakthrough Device Designation (2018) on the closest analog mechanism, but no 510(k) (premarket notification) clearance or De Novo (De Novo classification request) grant for it has been located; device_class frontmatter itself carries two unresolved candidate routes
What would settle it: openFDA 510(k) database search for a cleared ECG-hyperkalemia-screening predicate (by product code); FDA (US Food and Drug Administration) De Novo database search for the same
Why it scored what it did: Claims 4-7, 10: RAPID notice is a proposed rule with an open comment period (closing 2026-10-13), not in force; eligibility requires Breakthrough designation and "separately payable" status this device does not yet have; no HCPCS (Healthcare Common Procedure Coding System) code,…the rest of this reasoning
payment rate, or coverage policy identified for the service
What would settle it: Federal Register docket 2026-16368's finalization status; a CMS (Centers for Medicare & Medicaid Services) HCPCS/RPM code and LCD (local coverage determination)/NCD coverage-policy lookup. Both free, public CMS records.
Why it scored what it did: Claims 8-10: HF+CKD (chronic kidney disease) comorbidity prevalence reported 20-67% across reviewed studies, US RAASi prescription prevalence ~52%, USRDS 2024 ADR referenced but no beneficiary count extracted — population plausibility only, no price point or…the rest of this reasoning
addressable-share estimate
What would settle it: USRDS 2024 Annual Data Report for a Medicare FFS (fee-for-service) CKD beneficiary count (free); CMS RPM (remote physiological monitoring) payment rate as a price proxy (free); a licensed market/claims report for addressable share (paid, human-attached).
Why it scored what it did: claim 13unverified: explicit open FTO (freedom to operate) question — AliveCor may hold patent claims on ECG-morphology-based potassium inference; no patent number identified, no search performed
What would settle it: USPTO (United States Patent and Trademark Office)/Google Patents assignee search for AliveCor and adjacent ECG-hyperkalemia patent families, down to a specific patent number
Why it scored what it did: claim 1unconfirmed (AliveCor already holds Breakthrough Designation on a closely-related mechanism, positioning this candidate as a fast-follower) combined with claim 13unverified's open FTO question
What would settle it: Patent landscape scan beyond bare FTO (claim scope, expiration dates) plus a count of other named entrants pursuing ECG-based hyperkalemia screening
Why it scored what it did: claim 3unconfirmed: Mayo Clinic-affiliated deep-learning model reported AUC ~0.88-0.89 for ECG-based hyperkalemia screening — abstract-only, single study, not read at full-text depth
What would settle it: Full-text primary-source read of PMID (PubMed identifier) 30942845 (methodology, validation cohort, external validation) plus a search for any subsequent prospective/multi-site validation study
Why it scored what it did: Claims 2, 7: no cleared predicate identified (implies a likely De Novo route with attendant cost/time burden); RAPID reimbursement pathway is a proposed rule, not final, comment period closing 2026-10-13, timeline uncertain
What would settle it: Published FDA De Novo review-timeline statistics for comparable product codes; Federal Register docket tracking for 2026-16368's finalization timeline
Why it scored what it did: claim 1unconfirmed: AliveCor already Breakthrough-designated on this exact mechanism space since 2018
What would settle it: FDA Breakthrough Device Designation public list plus a search for recent clearances/funding/launches in ECG-based hyperkalemia screening
Why it scored what it did: No claim in this file addresses internal portfolio fit — not a primary-source-checkable factor
What would settle it: Internal portfolio review (human judgment, Stage 6/7), not a connector lookup
Seven chairs, each answering from its own field. The verdict, and the first condition it set.
Not convened. No department has stated a position on this idea yet — a normal state, not a defect. /round-table idea-011 asks all seven.
Only verified counts toward a score. A low count is usually a statement about the tooling — an absent data file, an unset key — rather than about the idea.
No claim on this idea has been refuted.
No cheapest next test written yet — /wrap idea-011 names one.
Nothing is waiting on a decision. The next move above is work, not a choice.
Only verified counts toward a score. A low count is usually a statement about the tooling (an absent data file, an unset key) rather than about the idea.
unconfirmed (7 of them
literature-sourced findings that a first verifier attempt mistakenly tagged verified
before being corrected — see commit history), so factors-verified and the composite are
unchanged from the pre-research gate-check. The added evidence enriches Mechanism &
clinical risk and TAM context but does not move either factor from blank to scored.
Re-confirmed again 2026-08-26 after a second research round (claims 25-30) targeted
Regulatory pathway and TAM specifically. Result unchanged: still queued-research, 1/9
factors verified. claim 26verified (an eCFR/openFDA classification-metadata discrepancy) is newly
verified but was judged by the Scorer too tangential to this device's own regulatory
question to score Factor 1 — it confirms a data-quality quirk in an unrelated product-code
family, not that this device has (or lacks) a viable pathway. The round's most substantive
finding — no 510(k)/De Novo product code anywhere carries a hyperkalemia/electrolyte/
potassium indication, so this device would be a founding De Novo entrant rather than a
510(k) follow-on — stays unconfirmed by this repo's own design (absence-of-match via a
typed connector can't be upgraded past unconfirmed), even though it's a sharper, more
thoroughly-searched negative result than the first pass produced. TAM gained five new
literature claims (US GWTG-HF registry, DISCOVER CKD, a genuine US Medicare FFS HFpEF
beneficiary count, UK/Japan hyperkalemia-discontinuation data) but none clear a Stage 3
connector, so TAM stays blank. Recommend: this candidate has now had two research rounds
without moving off 1/9; a third pass on the same factors is unlikely to change the verdict
without new primary sources becoming available (a De Novo bulk-data file, a USRDS
beneficiary export, or a PATENTSVIEW_API_KEY) — those are procurement gaps for a human to
close, not further research to run.
it. Recommend /research idea-011 next, targeting: the regulatory-predicate question
(AliveCor KardiaK clearance/De Novo status), the Mayo Clinic mechanism evidence at
primary-source depth, TAM (comorbidity prevalence, RAASi utilization, epidemiology), and
FTO (a real patent search once a search tool/key is available).
To finish it:
## Wrap section with a **Cheapest next test:** lineNo human review is recorded. Shortlisting, legal and clinical sign-off and capital allocation are Tier 3: no agent in this repo makes or simulates one.
Runs only after a human shortlists the idea.
No loop record: nobody has written down what this idea rests on or convened a department on it. That is a normal state, not a defect. /front-end-loop idea-011 opens one.
Nobody has yet written down what this idea rests on and what it would cost to be wrong. Unassessed is a state, not a low score. /assess idea-011 adds it.
Click any step to see what it holds for this idea. donecurrentloopinghuman only
## Wrap section, as writtenThis candidate has no ## Wrap section yet. Run /wrap idea-011 to write one.
| Factor | Score | Why | What would settle it |
|---|---|---|---|
| Regulatory pathway | 2 | Claims 1-2: AliveCor received Breakthrough Device Designation (2018) on the closest analog mechanism, but no 510(k) clearance or De Novo grant for it has been located; device_class frontmatter itself carries two unresolved candidate routes | openFDA 510(k) database search for a cleared ECG-hyperkalemia-screening predicate (by product code); FDA De Novo database search for the same |
| Reimbursement pathway | 1 | Claims 4-7, 10: RAPID notice is a proposed rule with an open comment period (closing 2026-10-13), not in force; eligibility requires Breakthrough designation and "separately payable" status this device does not yet have; no HCPCS code,…the rest of this reasoningpayment rate, or coverage policy identified for the service | Federal Register docket 2026-16368's finalization status; a CMS HCPCS/RPM code and LCD/NCD coverage-policy lookup. Both free, public CMS records. |
| TAM | 2 | Claims 8-10: HF+CKD comorbidity prevalence reported 20-67% across reviewed studies, US RAASi prescription prevalence ~52%, USRDS 2024 ADR referenced but no beneficiary count extracted — population plausibility only, no price point or…the rest of this reasoningaddressable-share estimate | USRDS 2024 Annual Data Report for a Medicare FFS CKD beneficiary count (free); CMS RPM payment rate as a price proxy (free); a licensed market/claims report for addressable share (paid, human-attached). |
| FTO / IP | 2 | claim 13unverified: explicit open FTO question — AliveCor may hold patent claims on ECG-morphology-based potassium inference; no patent number identified, no search performed | USPTO/Google Patents assignee search for AliveCor and adjacent ECG-hyperkalemia patent families, down to a specific patent number |
| Moat / defensibility | 2 | claim 1unconfirmed (AliveCor already holds Breakthrough Designation on a closely-related mechanism, positioning this candidate as a fast-follower) combined with claim 13unverified's open FTO question | Patent landscape scan beyond bare FTO (claim scope, expiration dates) plus a count of other named entrants pursuing ECG-based hyperkalemia screening |
| Mechanism & clinical risk | 3 | claim 3unconfirmed: Mayo Clinic-affiliated deep-learning model reported AUC ~0.88-0.89 for ECG-based hyperkalemia screening — abstract-only, single study, not read at full-text depth | Full-text primary-source read of PMID 30942845 (methodology, validation cohort, external validation) plus a search for any subsequent prospective/multi-site validation study |
| Capital intensity & time-to-revenue | 2 | Claims 2, 7: no cleared predicate identified (implies a likely De Novo route with attendant cost/time burden); RAPID reimbursement pathway is a proposed rule, not final, comment period closing 2026-10-13, timeline uncertain | Published FDA De Novo review-timeline statistics for comparable product codes; Federal Register docket tracking for 2026-16368's finalization timeline |
| Competitive intensity | 2 | claim 1unconfirmed: AliveCor already Breakthrough-designated on this exact mechanism space since 2018 | FDA Breakthrough Device Designation public list plus a search for recent clearances/funding/launches in ECG-based hyperkalemia screening |
| Strategic fit & portfolio balance | — | No claim in this file addresses internal portfolio fit — not a primary-source-checkable factor | Internal portfolio review (human judgment, Stage 6/7), not a connector lookup |
To finish this packet:
## Wrap section with a **Cheapest next test:** lineSource file: knowledge-base/candidates/idea-011.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.
_shared/plain-language.md